Sensei Biotherapeutics, Inc. (SNSE): Nasdaq/NYSE listing notice — Sensei Biotherapeutics regains Nasdaq minimum bid price compliance

Sensei Biotherapeutics, Inc.

Received Nasdaq letter on July 2, 2025 confirming compliance with Rule 5550(a)(2).
Closing bid price was at or above $1.00 for 10 consecutive business days (June 17 to July 1, 2025).
No further action required; delisting risk removed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sensei Biotherapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 2, 2025, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registra

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-157113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.